COMMUNIQUÉS West-GlobeNewswire

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
30/12/2024
ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) ACCORD-2 Phase 3 trial achieves key secondary endpoint compared to placebo (p=0.001, [...]
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
30/12/2024
Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III advanced liver cancer study Ramat Gan, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) -- [...]
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
30/12/2024
Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility DURHAM, N.C., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose [...]
Orion and Marinus terminate agreement for ganaxolone in Europe
30/12/2024
ORION CORPORATION PRESS RELEASE 30 DECEMBER 2024 at 14.00 EET Orion and Marinus terminate agreement for ganaxolone in Europe Orion Corporation (“Orion”) and Marinus Pharmaceuticals, Inc. (“Marinus”) have decided to [...]
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies
30/12/2024
Raanana, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
European Commission approves RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
30/12/2024
This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line treatment of patients with EGFR-mutated NSCLC 1 In the Phase 3 MARIPOSA study, amivantamab plus [...]
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
30/12/2024
Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec [...]
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
29/12/2024
MELBOURNE, Australia and INDIANAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application [...]
Innovative AI Law service to assist the less fortunate in civil rights cases: VRN News
29/12/2024
BOSTON, Dec. 29, 2024 (GLOBE NEWSWIRE) -- The more-than-likeness of Google's Willow chip and AI-119 Gen AI patent technology have led to the development of AI Legal Mate, an AI Law research organization that aims to [...]
Lifeward Announces Postponement of its Extraordinary General Meeting of Shareholders
27/12/2024
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what [...]
Psyence Biomed Announces Closing of $2.0 Million Private Placement
27/12/2024
NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has closed its previously announced private placement for the purchase and [...]
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
27/12/2024
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company’s pipeline PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a [...]
SAFE GROUP - Half-Year Financial Report as of June 30, 2024
27/12/2024
HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2024 December 27, 2024, 6.00 p.m. Safe Group announces that it has made available to the public and filed with the Autorité des Marchés Financiers its half-year financial report [...]
SAFE GROUP - Mise à disposition du rapport financier semestriel
27/12/2024
Mise à disposition du rapport financier semestriel Fleurieux-sur-l’Arbresle - France - le 27 décembre 2024 à 18h . Safe Group annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des Marchés [...]
LYNN STOCKWELL ENTERS INTO A RESTRUCTURING SECURITY AGREEMENT (“RSA”) WITH BRIGHT GREEN CORPORATION AND ASSUMES THE ROLE OF EXECUTIVE CHAIR AND CEO.
27/12/2024
GRANTS, NEW MEXICO, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) (“Bright Green” or the “Company”) announced today that Lynn Stockwell has agreed to terms for a restructuring security agreement [...]
Vor Bio Announces $55.6 Million Private Placement
27/12/2024
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33 ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second [...]
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
27/12/2024
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in H1 CY25 Received [...]
WEED Inc. President and CEO Releases Letter to Shareholders
27/12/2024
TUCSON, Ariz., Dec. 27, 2024 (GLOBE NEWSWIRE) -- via IBN – WEED Inc. (OTCQB: BUDZ ) , (“WEED,” “HEMP” or the “Company”), a global cannabis and hemp bioresearch company based in the U.S., shares the Company’s 2025 plans [...]
Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
27/12/2024
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “ Company ”), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in [...]

Pages